The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...
MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...
Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...
Adding PSMA-based radioligand therapy to metastasis-directed SBRT in men with oligorecurrent prostate cancer delays progression, defined by PSMA PET/CT. As PSMA-targeting RLT improves survival ...
Disparities in guideline-concordant treatment receipt for localized prostate cancer (PCa): A SEER-based analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...
The assay is designed to encourage informed patient-physician decision-making when choosing a treatment option in localised ...
A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, after ...
Addition of 6 months of androgen deprivation therapy to stereotactic body radiotherapy more than doubled PFS in hormone-sensitive oligorecurrent prostate cancer. Nearly all patients treated with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results